key: cord-0877102-68ps3uit
authors: Schmid-Burgk, Jonathan L.; Schmithausen, Ricarda M.; Li, David; Hollstein, Ronja; Ben-Shmuel, Amir; Israeli, Ofir; Weiss, Shay; Paran, Nir; Wilbring, Gero; Liebing, Jana; Feldman, David; Słabicki, Mikołaj; Lippke, Bärbel; Sib, Esther; Borrajo, Jacob; Strecker, Jonathan; Reinhardt, Julia; Hoffmann, Per; Cleary, Brian; Hölzel, Michael; Nöthen, Markus M.; Exner, Martin; Ludwig, Kerstin U.; Regev, Aviv; Zhang, Feng
title: LAMP-Seq: Population-Scale COVID-19 Diagnostics Using Combinatorial Barcoding
date: 2020-06-08
journal: bioRxiv
DOI: 10.1101/2020.04.06.025635
sha: f679c76c17b52657bf99d640dcb1df955bd8e364
doc_id: 877102
cord_uid: 68ps3uit

The ongoing SARS-CoV-2 pandemic has already caused devastating losses. Exponential spread can be slowed by social distancing and population-wide isolation measures, but those place a tremendous burden on society, and, once lifted, exponential spread can re-emerge. Regular population-scale testing, combined with contact tracing and case isolation, should help break the cycle of transmission, but current detection strategies are not capable of such large-scale processing. Here we present a protocol for LAMP-Seq, a barcoded Reverse-Transcription Loop-mediated Isothermal Amplification (RT-LAMP) method that is highly scalable. Individual samples are stabilized, inactivated, and amplified in three isothermal heat steps, generating barcoded amplicons that can be pooled and analyzed en masse by sequencing. Using unique barcode combinations per sample from a compressed barcode space enables extensive pooling, potentially further reducing cost and simplifying logistics. We validated LAMP-Seq on 28 clinical samples, empirically optimized the protocol and barcode design, and performed initial safety evaluation. Relying on world-wide infrastructure for next-generation sequencing, and in the context of population-wide sample collection, LAMP-Seq could be scaled to analyze millions of samples per day.

As of June 2020, the global spread of a novel coronavirus, SARS-CoV-2, has resulted in over 6,700,000 confirmed cases and 393,000 deaths (Johns Hopkins CSEE Covid tracker (Dong et al., 2020) ). Early epidemiological studies indicate that the exponential spread of COVID-19, the disease caused by SARS-CoV-2, can be slowed by restrictive isolation measures (Chinazzi et al., 2020) , but these measures place an enormous burden on societies and economies. Moreover, once isolation measures are lifted, exponential spread is predicted to resume . At the same time, many infected individuals do not show any symptoms, remain untested, and thereby unknowingly contribute to the spread of infection . Repeated population-scale testing that enables identification of all infected individuals regardless of their symptomatic or contact status was predicted as an effective measure to help combat the transmission of SARS- CoV-2 (Taipale et al., 2020) , pinpoint outbreak areas, and enable local epidemiological interventions that maximize human health, while minimizing the extent of restrictive isolation measures.

Currently, most testing for active SARS-CoV-2 infection is performed using viral RNA extraction followed by RT-qPCR to amplify and detect several highly conserved regions of the SARS-CoV-2 genome. The global capacity for testing using this approach, however, has been limited in several ways. Initially, access and supply of reagents and instruments were limited considering the surge in demand. Second, this protocol requires a number of hands-on steps that must be performed by trained professionals, hampering its scalability, although automated systems do increase scale.

Third, while several sequencing-based PCR approaches have been proposed (https://docs.google.com/document/d/1kP2w_uTMSep2UxTCOnUhh1TMCjWvHEY0sUUpkJH 4 PYV4, https://www.notion.so/Octant-SwabSeq-Testing-9eb80e793d7e46348038aa80a5a901fd -639fd74b2ff14daf9a3b78bac1c738b1), their throughput is constrained by the availability of required devices like thermocyclers. Finally, and most critically, even as some of these bottlenecks have been reduced by automation and better supply chains, massive, repeated population testing is hampered by the need to collect samples in centralized settings, and to process each of them individually.

Here, we demonstrate LAMP-Seq, a novel protocol that allows for population-scale testing using massively parallel RT-LAMP (Nagamine et al., 2002; Notomi et al., 2000) by employing samplespecific barcodes. This approach requires only three heating steps for each individual sample, followed by pooled processing, parallelized deep sequencing, and well-established computational analysis. By using a simple thermal protocol for processing individual samples and pooling many samples prior to resource-intensive steps, the requirement for specialized reagents, equipment, and labor is greatly reduced relative to alternative protocols. Unique tracking of hundreds of millions of samples as well as asynchronous testing logistics, including at-home collection, can be achieved by employing a compressed barcode space. We describe the design of LAMP-Seq, validation on clinical specimens, and simulated barcoding strategies. We estimate that the cost per sample would be < 20 USD based on current list-prices of off-theshelf products (excluding labor and instrument costs), with a potential for at least 10-fold cost reduction through scaled sourcing of three enzymes (RTx, Bst 2.0, Bst 3.0). Most importantly, this approach is predicted to be scalable to hundreds of thousands of samples per day per sequencing facility and could be deployed in developing countries.

We devised LAMP-Seq as an approach for population-scale testing for SARS-CoV-2 infection with the following overall steps ( Fig. 1A-C) : a barcoded RT-LAMP reaction is performed on an unpurified or lysed swab sample with primers specific for the SARS-CoV-2 genome, which is followed by large-scale pooling of samples, PCR amplification with additional barcoding, deep sequencing, and data analysis to identify positive individuals (Fig. 1A, B ; see below for detailed protocol). RT-LAMP reactions have been demonstrated to be highly sensitive for sequencespecific viral nucleic acid detection (Lamb et al., 2020; Yang et al., 2020; Zhang et al., 2020) , even from unpurified samples (Estrela et al., 2019) . To establish a barcoded RT-LAMP reaction, we inserted barcode sequences into the forward inner primer (FIP), which enables generation of barcoded palindromic amplification products (Fig. 1C) . When a small fraction of samples is expected to be positive during population scale testing, we can further limit the number of unique barcode primers needed for testing a large number of samples, by using a compressed barcode space (below).

Specifically, we designed three barcoded primer sets based on validated RT-LAMP amplicons (Table S1 , (Broughton et al., 2020; Lamb et al., 2020; Zhang et al., 2020) ) perfectly matching 95.0% (amplicon A), 95.4% (amplicon B), and 96.8% (amplicon C) of 4,406 SARS-CoV-2 genomes available in the NCBI database (May 30th, 2020). 10-nt barcodes with GC content of 30%-70% and lacking homopolymer repeats of four or more nucleotides were inserted into the FIP primer. We ensured that barcodes are robust to sequencing errors by a minimum Levenshtein edit distance between any barcode pair sufficient to detect two insertion, deletion or substitution errors (Table S1) . 6 Comparing barcoded LAMP reactions to non-barcoded controls using a dsDNA surrogate template for SARS-CoV-2, we confirmed that the presence of a prototypical 10-nt barcode within the FIP primer did not affect LAMP sensitivity, product amounts, or downstream PCR amplification (Fig.   1D ). Templating two individually barcoded LAMP reactions that differ 100-fold in the amount of dsDNA template, combining them for PCR amplification, and sequencing the products resulted in read numbers within a two-fold range between the two samples ( Fig. 1E) , indicating that RT-LAMP saturation can effectively compress the dynamic range of input viral loads. This might be beneficial when analyzing many samples together on a sequencing run. Furthermore, we confirmed the expected sequence of barcoded RT-LAMP-PCR products by Illumina sequencing (Fig. 1F) . In order to determine the molecular sensitivity of barcoded RT-LAMP reactions, we performed 24 reactions with differing numbers of template RNA molecules, and determined positive subsequent PCR reactions by gel electrophoresis (Fig. 1G) . Using a constant per-molecule probability model of RNA detection, the maximum likelihood estimate for molecular detection efficiency is 1/35.5 per RNA molecule (Fig. 1H ) which corresponds to an LoD-95 of 105 molecules. This is about an order of magnitude less sensitive than RT-qPCR (https://www.fda.gov/media/134922/download).

To validate LAMP-Seq, we tested 28 human samples side-by-side with a standard clinical diagnostic by RT-qPCR with a human subjects protocol approved by the ethics committee of the University Hospital Bonn. Two oropharyngeal samples were collected from each individual using two separate cotton swabs, which were anonymized using an individual ID. One swab was analyzed using a standard clinical diagnostics pipeline comprising rehydration, robotic RNA 7 purification, and RT-qPCR ( Fig. 2A, upper panel) . The other swab was immediately inserted into a tube containing QuickExtract lysis buffer (Joung et al., 2020) (Fig. 2A , lower panel), processed and sequenced according to the LAMP-Seq protocol using individual PCR barcodes (Methods).

The two methods were in complete agreement on both positives and negatives (Fig. 2B, C) : All 12 individuals identified as SARS-CoV-2 RNA positive by RT-qPCR were also detected positive using LAMP-Seq employing a threshold of 10,000 reads; the remaining 16 individuals were identified as negative for viral RNA in agreement between both methods (Fig. 2B, C) , with an average of 962 LAMP-Seq reads per negative sample, putatively arising from barcode swapping.

Of note, N-gene-specific primers have been reported to be slightly less sensitive in RT-qPCR than primers for other targets (Corman et al., 2020) . Unfiltered LAMP-Seq sequencing data confirmed the expected read structure, comprising primer sequences, viral genome sequence, and a matching barcode in 67% of reads (Fig. 2D) , while the majority of remainder reads bore single-nucleotide substitutions or truncations relative to the expected amplicon sequence.

Effective SARS-CoV-2 virus inactivation in QuickExtract lysis buffer was confirmed both after 30 minutes of incubation at 65 °C and after 10 minutes at 95 °C, resulting in at least a 3.9E4-fold reduction in viral infectivity (Table 1) , whereas residual SARS-CoV-2 infectivity was retained following 30 minutes incubation at 22 °C. To further investigate the inactivation efficiency of the lysis buffer, a high dose of VSV virus was used to demonstrate at least a 1E7-fold reduction in viral infectivity (Table 1) . We next optimized LAMP-Seq to allow successful pooling of barcoded RT-LAMP reactions, which is essential for scaling up LAMP-Seq, focusing on minimizing levels of barcode swapping, and on ensuring a sufficient number of individually validated barcodes. When we pooled six barcoded RT-LAMP reactions, of which three were templated with RNA, and performed PCR and sequencing, we observed moderate levels of barcode swapping (Fig. 2E , left panel). We hypothesized that barcode primers being transferred into the PCR reaction may lead to amplification and re-barcoding of amplicons. We eliminated detectable barcode swapping by diluting pooled RT-LAMP reactions one-million-fold in the PCR reaction, which ( Fig. 2E , right panel). Next, pooling 480 barcoded FIP primers, performing RT-LAMP reactions in four replicates, and sequencing the barcode distribution in resulting products revealed that ~5% of barcode sequences perform poorly or even fail to engage in LAMP-Seq (Fig. 2F) . Investigating potential sequence determinants that could guide optimized barcode design, we observed that the least efficient barcode primers displayed a marked enrichment for a GTCC motif or truncations thereof, especially towards the 3' end of the barcode (Fig. 2F , inset). As this motif is the reverse complement of the 3' end of the FIP primer, we hypothesize it could sequester the 3' end by 9 forming an intramolecular structure, thus inhibiting elongation of the primer, and should be avoided. Following this rule, we designed >6,000 barcoded FIP and BIP primers as well as provide 240 validated barcoded FIP primers for application of LAMP-Seq (Table S1) .

A high-output Illumina 75-cycle NextSeq run can routinely generate 200 million sequencing reads in 14 hours, which we predict is sufficient for 100,000 samples per run, even accounting for library skewing due to differences in viral loads (for modeling see Supplementary Note 1 and 2).

Barcoding 100,000 samples could be achieved by a naïve approach, where each sample is contacted with a unique barcode primer ( Fig. 3A , left). However, as synthesis, validation, and robotic handling of large numbers of barcode primers is challenging, we explored a compressed barcode space, where every sample would be assigned a unique combination of more than one barcode ( Fig. 3A , right). For this scenario, we conservatively assume that 1% of synthesized barcode primers systematically fail to work, even after removing barcode primers that contain homology to GTCC (∆ synth = 0.01), and that 5% of all sample-specific barcodes are not detected due to varying sequencing depth (∆ stoch = 0.05; independent of dropout due to low viral load). For automated assembly of testing reactions with unique barcode combinations, we anticipate that m = 1,000 barcode primers can be easily handled by available pipetting robots. Under these assumptions, we investigated for 100,000 samples what number of barcodes per sample (k), total number of barcode primers (m), and number of pools per run (m2) would minimize false-positive and false-negative rates of detection ( Fig. 3B-C) . Interpreting the compressed barcoding problem as a modified Bloom filter (Supplementary Note 1), we predict that when using k = 5 barcodes per sample, where k' = 3 barcodes are detected per sample, and splitting samples into m2 = 96 pools per run, both the false-negative and false-positive rates of detection using a compressed barcode space will be less than 0.2% as long as the global frequency of positive samples is below 1.2%

( Fig. 3B) . Larger numbers of barcodes will further lower error rates and ensure performance in the face of higher global positive frequencies (Fig. 3C) .

As some barcoded FIP primers fail in the RT-LAMP reaction, it may be advantageous to reduce the number of barcode primers that need to be validated. One way to achieve this is with a dual barcoding scheme, where both the FIP and BIP primers are barcoded (Fig. 3D) . Using Tn5- This dual barcoding scheme would eliminate errors due to systematic barcode failure, but introduces the possibility of template switching errors. To explore parameters for this scheme, we assume that 5% of all sample-specific barcode pairs are not detected due to varying sequencing depth (∆ stoch = 0.05; this is independent of dropout due to low viral load) and that template switching occurs 2% of the time (∆ switch = 0.02). Under these assumptions, numerical simulations of this dual barcoding scheme (Fig. 3F ,G, Supplementary Note 2) suggests that both the false-negative and false-positive rates of detection will be less than 0.2% as long as the global frequency of positive 11 samples is below 1.6% when using a set of 96 FIP barcodes (m1 = 96), 96 BIP barcodes (m2 = 96), with 3 of each barcode per patient sample (k1, k2 = 3), requiring 6 out of 9 barcode pairs to be detected for a positive sample (k12' = 6), and 10 pools per run (m3 = 10) (Fig. 3G) . Increasing the number of barcoded FIP and BIP primers to 192 or 384 each and changing the required threshold to 5 out of 9 barcode pairs detected for a positive sample (k12' = 5) lowers the error rates and allows for higher global frequencies of positive samples (Fig. 3F) . We emphasize that the simulated compressed barcoding schemes have not been experimentally validated yet.

LAMP and RT-LAMP (Nagamine et al., 2002; Notomi et al., 2000) have been previously established for use as highly sensitive methods for pathogen detection from unpurified human samples with detection limits below 100 nucleic acid molecules (Mori and Notomi, 2009) .

Although colorimetric or turbidimetric readouts of LAMP reactions can suffer from false positive results (Estrela et al., 2019) , here we demonstrate that a sequencing-based readout provides maximum specificity by detecting only correct fusions of barcode sequences with two stretches of viral sequence. In addition, we show that this novel multiplexing-LAMP strategy can be made robust against barcode cross-contamination originating from template switching events or primer contamination at the PCR stage, as two template switching events would be required in order to create a sequencing-compatible amplicon.

We developed and optimized a barcoded RT-LAMP protocol (LAMP-Seq) and successfully validated it on 28 human swab samples. The current protocol does not require RNA purification or individual processing steps except using approximately one pipette tip per sample, which can be automated through using matrix-format tubes at the stage of swab lysis. Of note, larger numbers of patient samples need to be tested before proposing deployment of LAMP-Seq for population screening. Larger sample sizes will also allow exploration of the possibility of rare inhibitory compounds in some unpurified human samples, potentially resulting from food intake, hygiene interventions, or the oral microbiome. Apart from further validation studies, compatibility of the current LAMP-Seq protocol with other types of human samples (saliva, sputum, anterior nasal (AN) swabs, mid-nasal swabs, fecal samples) should be explored rapidly to identify the most scalable solution for unsupervised at-home sample collection, which would be attractive if the safety can be guaranteed during shipping of inactivated samples. For deployment, LAMP-Seq also has to be equipped with a positive control amplicon to ensure efficient RT-LAMP processing of each individual sample, which could run in the same RT-LAMP reaction or in a separate reaction, allowing independent saturation of both amplicons. Of note, the compressed barcoding schemes would require the positive control template to bear an additional heterogeneous sequence portion.

A major advantage of LAMP-Seq is that barcoding is performed early in the protocol using a simple heating device (like an oven), whereas downstream processing of sequencing libraries is done on large pools of samples. To enable pooled processing, we show that multiple barcode sequences can be inserted into the forward inner primer (FIP) and / or backward inner primer (BIP) primer used during an RT-LAMP reaction, as long as a simple sequence motif is avoided in all barcode sequences. As all barcodes have to be experimentally validated for diagnostic use, we

propose and mathematically simulate a dual-indexing scheme that would allow uniquely barcoding more than 100,000 samples per run while only requiring 192 validated barcoded FIP/BIP primers.

A potential limitation of the presented approach is that skewing of sample representation at the pooling stage may affect testing sensitivity. Although the LAMP reaction saturates in positive samples largely independent of template concentrations (Fig. 1E) , thus equalizing the representation across positive samples in an advantageous manner, the reaction might also add random skewing to pooled samples when scaling to hundreds of thousands of samples; however, preliminary modeling suggests that pooling 100,000 samples per NextSeq run offers robust detection ( Supplementary Note 1 and 2) . 

LAMP-Seq testing for SARS-CoV-2 N-gene 1. A freshly inoculated cotton dry swab (nerbe plus GmbH, 09-819-5000) is inserted into 500 µl of QuickExtract (Lucigen, QE09050) supplemented with 2 ng/µl RNase-free plasmid DNA (pX330, Addgene #42230) in a 15 ml Falcon tube, stored on ice for transport, incubated for at least 10 minutes at room temperature, and heated to 95 °C for 5 minutes. 4. The RT-LAMP reaction is heated to 65 °C for 1 hour, and to 95 °C for 10 minutes.

5. Up to 100,000 reactions are pooled in batches of 1,000 to 10,000 samples per batch.

6. The pool is diluted 1:100,000 in water. Handling and working with VSV was conducted in a BSL-2 facility in accordance with the biosafety guidelines of the IIBR. 

The LAMP-Seq Inspector tool for processing raw LAMP-Seq data is available at: 

Fast and accurate diagnostics from highly multiplexed sequencing assays

Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay

The effect of travel restrictions on the spread of the 2019 novel coronavirus

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

An interactive web-based dashboard to track COVID-19 in real time

Ten-minute direct detection of Zika virus in serum samples by RT-LAMP

Point-of-care testing for COVID-19 using SHERLOCK diagnostics

Rapid Detection of Novel Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal Amplification

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)

Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases

Accelerated reaction by loop-mediated isothermal amplification using loop primers

Loop-mediated isothermal amplification of DNA